Amarin reported $649.88M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amarin USD 649.88M 21.55M Dec/2025
AstraZeneca USD 28.72B 1.22B Dec/2025
BioCryst Pharmaceuticals USD 404.35M 48.66M Dec/2025
DBV Technologies USD 88.88M 32.36M Sep/2025
Esperion Therapeutics USD 462.57M 102.11M Dec/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
Halozyme Therapeutics USD 825.21M 503.54M Dec/2025
Heron Therapeutics USD 238.07M 8.67M Dec/2025
Ionis Pharmaceuticals USD 2.99B 471.01M Dec/2025
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Novartis USD 30.46B 2.26B Dec/2025